Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Jun 3, 2011

Premium

Bruker announced this week that chief financial officer Brian Monahan has stepped down from his position in order to spend more time with his family. Chief operating officer and former CFO William Knight will serve as interim CFO while the company searches for Monahan's replacement.

Monahan will be staying with the company as vice president of strategic and financial planning.


Silicon Kinetics said this week it has named John Ervin as president and appointed him and Robert Fein to its board of directors.

Ervin was previously the company's director of R&D and engineering. Before that he worked at Eksigent, Ultradots, and Perseptive Biosystems.

Fein is the managing director of Back Bay Management Consulting Group and was previously an officer and founder of NewRiver and Perseptive Biosystems and the director of corporate strategy for Thermo Electron, now part of Thermo Fisher Scientific.


Denator announced this week that it has appointed Martin Nicklasson to its board of directors.

Nicklasson is currently a board member of the Swedish Heart & Lung Foundation, Scandanavian Life Science Invest, and Biocrine and previously was CEO at AstraZeneca and Biovitrum.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.